AbbVie to Expand Oncology Presence Through Acquisition of Stemcentrx and its Novel, Late-Stage Rova-T Compound for Small Cell Lung Cancer
Go back to AbbVie to Expand Oncology Presence Through Acquisition of Stemcentrx and its Novel, Late-Stage Rova-T Compound for Small Cell Lung Cancer| AbbVie (NYSE: ABBV) | Delayed: 265.12 +1.16 (0.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $263.96 | 52 Week High | $68.12 | |||
| Open | $263.07 | 52 Week Low | $50.71 | |||
| Day High | $266.60 | P/E | 57.51 | |||
| Day Low | $261.23 | EPS | $4.61 | |||
| Volume | 748,452 | |||||
